💸 The Tape

The House passed the continuing resolution 370-48 on Tuesday, sending it to President Trump's desk with the hemp provision intact. The Senate had already cleared it 90-6, after rejecting Sen. Ted Budd's amendment to strip the delay by a 61-32 tabling vote.

Worth being direct: three weeks ago the House had passed its own funding bill with no hemp language at all, and the odds of it swallowing the Senate's version looked poor. It swallowed it by a seven-to-one margin. The White House supports the provision, and Trump is expected to sign.

So the federal hemp recriminalization moves from November 12 to December 11. That's the win. Here's everything it doesn't do.

The carve-out is not small

The delay contains an exception permitting immediate recriminalization on November 12 of synthetic cannabinoids "not capable of being naturally produced by a Cannabis sativa L. plant."

Note the precise language — capable of being naturally produced, not naturally derived. That distinction is the entire legal test, and a lot of marketing copy currently gets it wrong. Delta-8 and HHC are converted from CBD in a lab. Whether they clear the "capable of being naturally produced" bar is a fight that will be litigated by manufacturers, but the drafting intent is fairly plain.

Which means the isomer business — the category that built gas-station THC — is still very likely dying on the original schedule. What got extended is full-spectrum CBD and hemp beverages: the products with mainstream lobbying muscle behind them.

The immovable object

The underlying statute hasn't changed. Legislation signed late last year redefines hemp so only products with 0.4 milligrams of total THC per container remain legal after the effective date. That threshold kills virtually every hemp delta-9 edible and beverage on the market today.

Congress has now moved the date. It has not touched the definition.

Next steps, in order

Signature. Trump signs, likely within days. The delay is then law.

November 12. Synthetic cannabinoids get recriminalized regardless. Expect enforcement confusion, state-by-state divergence, and litigation over what "capable of being naturally produced" means.

The legislative window. Roughly fourteen weeks to pass an actual framework. Three vehicles exist:

Van Duyne-Landsman would keep hemp THC drinks legal at 5mg per serving, tax them at 8 cents per milligram, regulate through TTB, HHS and USDA, and route distribution through the three-tier alcohol system.

Rep. James Comer, who chairs House Oversight, is circulating a narrower bill — delay plus packaging requirements, testing rules and age limits.

Rep. Andy Barr filed the longest version, covering manufacturing, labeling, sales, taxation and a 21 age limit. A Senate companion is expected from Sens. Tim Sheehy (R-MT) and Amy Klobuchar (D-MN).

December 11. Government funding expires and the hemp ban takes effect on the same day. Same cliff, same room, holiday calendar.

What can actually happen before then

Scenario one: a framework passes. This is now genuinely plausible in a way it wasn't a month ago. The coalition has real weight — the Beverage Alcohol Merchants Coalition (Total Wine, BevMo, ABC Fine Wine, Spec's), the Wine & Spirits Wholesalers of America, the National Restaurant Association, and the White House. Target just expanded hemp THC drink sales into more states. When alcohol wholesalers want a category inside their distribution system, things tend to move.

The obstacle is money. WSWA endorsed Barr's bill but said its tax provisions need continued discussion — meaning nobody has agreed on the rate. That's not a detail; excise structure is usually the last thing settled and the thing that kills bills.

Scenario two: the ban takes effect December 11. Congress does what it usually does, runs out of time, and the 0.4mg threshold becomes operative. Full-spectrum CBD, hemp beverages, and edibles exit the legal market nationwide — a California-style shutdown at federal scale.

Scenario three: another delay. Publicly foreclosed. White House Director of Legislative Affairs James Braid reportedly told Senate Republicans in a tense meeting that there would be no further extensions if this one passed. Though it was reported shortly after that Braid is leaving the administration in September, which makes that commitment considerably less binding than it sounded.

Scenario four: a narrow CBD-only fix. The most likely partial outcome. Trump's own advocacy has been specifically about full-spectrum CBD — he's cited one in five adults using it and pushed to protect access. CMS Administrator Dr. Oz wrote senators expressing grave concern that killing the delay would undermine the administration's Medicare initiative, which covers up to $500 annually of hemp-derived products for eligible patients, allowing up to 3mg of total THC per serving. That program survived a legal challenge; the dismissal is on appeal. CBD has White House sponsorship. Intoxicating hemp does not.

The opposition is not trivial

Thirty-five state and territory attorneys general — bipartisan — sent a letter urging Congress not to reverse the ban, arguing the prohibition protected consumers, provided regulatory clarity, and preserved legitimate industrial and non-intoxicating hemp markets. Dueling coalitions of police and veterans groups have filed on both sides.

And there's a political vulnerability: the White House has had to publicly deny that Trump's hemp advocacy is aimed at benefiting the son-in-law of his chief of staff, who owns businesses in the industry. Whatever the merits, that's a line of attack available to anyone who wants to slow this down.

What operators should do

Payment processors are already moving ahead of Congress. Square has told businesses to stop selling hemp and CBD products in light of the coming ban. Banking and payments will tighten before the legal deadline arrives, regardless of what passes.

None of this reopens Texas or Ohio. Those are state actions, unaffected by federal timing. And NuggMD polling confirms state-level bans are pushing consumers toward licensed marijuana retailers — a channel-shift benefit already banked for MSOs.

Fourteen weeks, a tax rate nobody has agreed on, and a funding fight sharing the same date. The industry got its extension. Now it has to build something before the clock runs out again.

📈 Dog Walkers

$CMND ( ▼ 5.67% ) Hits Milestone

Clearmind Medicine Inc. (Nasdaq: CMND) has initiated Phase IIa of its double-blind, placebo-controlled Phase I/IIa trial evaluating CMND-100 for alcohol use disorder, with six patients enrolled — three at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem.

That marks the first multiple-dose treatment phase of Part C, following completion of the safety portion in healthy volunteers. An independent Data and Safety Monitoring Board reviewed Part A data and recommended advancing, which is the clearance that made this possible.

The trial is a four-part study assessing safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate-to-severe AUD.

The distinguishing feature of CMND-100 is what it isn't. Clearmind is developing non-hallucinogenic psychedelic-derived neuroplastogens — compounds intended to deliver the neuroplasticity benefits without the trip. That matters commercially: a therapy requiring eight hours of supervised dosing has a fundamentally different reimbursement and scalability profile than a pill. Clearmind's stated aim is scalable treatment, and that word is carrying the thesis.

The target is real. AUD affects tens of millions with limited effective treatment options — a genuine unmet need rather than a crowded field.

Two things to keep in proportion. Six patients is the beginning of Phase IIa, not a data readout, and headline enrollment milestones aren't efficacy. And a company whose portfolio runs to 19 patent families and 32 granted patents is still years from an approval pathway.

The tailwind is timing. Dr. Heidi Overton, reportedly involved in drafting the April executive order prioritizing psychedelic therapies, is Trump's FDA nominee. Clearmind separately advanced MDMA-N-acylethanolamines IP for PTSD last month.

The regulatory door is opening. The data still has to walk through it.

📺 Trade To Black

House Votes Today on Hemp Ban Delay | TTB Presented by Flowhub

• Consumers distrust unregulated products — then buy them anyway. This week's Check-In Poll, presented by NuggMD, found only 20% actually check testing before buying outside a licensed dispensary. Roughly 27% assume those products are tested, 26% assume they aren't, and 20% had never thought about it.

• The gap is dangerous. NuggMD's Tyler Elson explains that unregulated products aren't held to state-legal testing standards — creating real risk around inaccurate labeling, inconsistent THC levels, and contaminants like pesticides and heavy metals. Earlier NuggMD data found 75% of products from unlicensed shops failed contamination testing.

• The House votes on the hemp delay. Michael Bronstein of ATACH returns for Insiders Edge to break down the funding bill pushing the federal hemp THC ban from November 12 to December 11 — and what's actually at stake in the shift to a 0.4mg total THC per container standard that would wipe out much of today's beverage and gummy market.

• Four competing frameworks, and an unexpected ally. Bronstein walks through the proposals from Andy Barr, Beth Van Duyne, Greg Landsman and James Comer — and why parts of the alcohol industry are now pushing for regulation over outright prohibition.